The skeletal consequences of growth hormone therapy in dialyzed children: a randomized trial.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

The effects of recombinant human growth hormone on renal osteodystrophy are unknown; thus, the effects of growth hormone (GH) on bone histomorphometry were assessed in pediatric patients with ESRD.

Who Took Part

By PubMed's age tags, the people studied were young children, children, teenagers and young adults, both men and women.

Thirty-three patients who underwent bone biopsy between July 1994 and May 1999 were randomly assigned to therapy with or without GH.

Patients were stratified by bone formation rate; all patients with high bone turnover received intraperitoneal calcitriol.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

What Was Measured

The subject headings attached to it are Analysis of Variance, Biomarkers, Biopsy, Body Height, Bone and Bones, Chronic Kidney Disease-Mineral and Bone Disorder and Human Growth Hormone.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2013 (Clinical journal of the American Society of Nephrology : CJASN), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.